NASDAQ:CRVS Corvus Pharmaceuticals (CRVS) Stock Price, News & Analysis $3.49 +0.02 (+0.58%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$3.49 0.00 (0.00%) As of 05/23/2025 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Corvus Pharmaceuticals Stock (NASDAQ:CRVS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Corvus Pharmaceuticals alerts:Sign Up Key Stats Today's Range$3.38▼$3.5150-Day Range$2.82▼$4.4352-Week Range$1.75▼$10.00Volume464,961 shsAverage Volume727,599 shsMarket Capitalization$237.91 millionP/E RatioN/ADividend YieldN/APrice Target$15.00Consensus RatingBuy Company OverviewCorvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.Read More… Corvus Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks44th Percentile Overall ScoreCRVS MarketRank™: Corvus Pharmaceuticals scored higher than 44% of companies evaluated by MarketBeat, and ranked 556th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingCorvus Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCorvus Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.Read more about Corvus Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Corvus Pharmaceuticals are expected to grow in the coming year, from ($0.63) to ($0.49) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Corvus Pharmaceuticals is -3.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Corvus Pharmaceuticals is -3.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCorvus Pharmaceuticals has a P/B Ratio of 4.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Corvus Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.46% of the outstanding shares of Corvus Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverCorvus Pharmaceuticals has a short interest ratio ("days to cover") of 6.2.Change versus previous monthShort interest in Corvus Pharmaceuticals has recently increased by 8.05%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCorvus Pharmaceuticals does not currently pay a dividend.Dividend GrowthCorvus Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted8.46% of the outstanding shares of Corvus Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverCorvus Pharmaceuticals has a short interest ratio ("days to cover") of 6.2.Change versus previous monthShort interest in Corvus Pharmaceuticals has recently increased by 8.05%, indicating that investor sentiment is decreasing significantly. News and Social Media2.6 / 5News Sentiment0.67 News SentimentCorvus Pharmaceuticals has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Corvus Pharmaceuticals this week, compared to 2 articles on an average week.Search Interest6 people have searched for CRVS on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Corvus Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders28.50% of the stock of Corvus Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions46.64% of the stock of Corvus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Corvus Pharmaceuticals' insider trading history. Receive CRVS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Corvus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address CRVS Stock News HeadlinesCorvus Pharmaceuticals (NASDAQ:CRVS) Stock Rating Lowered by Wall Street ZenMay 23 at 3:11 AM | americanbankingnews.comMizuho Issues Pessimistic Forecast for Corvus Pharmaceuticals (NASDAQ:CRVS) Stock PriceMay 22 at 2:12 AM | americanbankingnews.comTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans a chance at true financial independence in the months ahead.” We recently sat down with Rickards to capture all the key details on tape. May 24, 2025 | Paradigm Press (Ad)Corvus Pharmaceuticals (NASDAQ:CRVS) Stock Rating Upgraded by StockNews.comMay 14, 2025 | americanbankingnews.comCorvus Pharmaceuticals Shares Surge on Study Data Evaluating SoquelitinibMay 10, 2025 | marketwatch.comCorvus Pharmaceuticals targets expanded soquelitinib trials with Q4 2025 results expectedMay 9, 2025 | msn.comCorvus Pharmaceuticals shares surge on positive trial resultsMay 9, 2025 | investing.comIs Corvus Pharmaceuticals, Inc. (CRVS) the Low Risk High Reward Stock Set to Triple by 2030?May 9, 2025 | uk.finance.yahoo.comSee More Headlines CRVS Stock Analysis - Frequently Asked Questions How have CRVS shares performed this year? Corvus Pharmaceuticals' stock was trading at $5.35 at the beginning of the year. Since then, CRVS stock has decreased by 34.8% and is now trading at $3.49. View the best growth stocks for 2025 here. How were Corvus Pharmaceuticals' earnings last quarter? Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) posted its quarterly earnings data on Thursday, May, 8th. The company reported ($0.13) EPS for the quarter, hitting analysts' consensus estimates of ($0.13). Read the conference call transcript. When did Corvus Pharmaceuticals IPO? Corvus Pharmaceuticals (CRVS) raised $75 million in an initial public offering (IPO) on Wednesday, March 23rd 2016. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Credit Suisse and Cowen and Company served as the underwriters for the IPO and Guggenheim Securities, Cantor Fitzgerald and BTIG were co-managers. Who are Corvus Pharmaceuticals' major shareholders? Corvus Pharmaceuticals' top institutional shareholders include Samlyn Capital LLC (5.96%), Towerview LLC (0.19%), Simplex Trading LLC and Wellington Management Group LLP (0.15%). Insiders that own company stock include Richard A Md Miller, William Benton Jones, Leiv Lea and Linda Grais. View institutional ownership trends. How do I buy shares of Corvus Pharmaceuticals? Shares of CRVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Corvus Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Corvus Pharmaceuticals investors own include NVIDIA (NVDA), Viking Therapeutics (VKTX), Advanced Micro Devices (AMD), ADMA Biologics (ADMA), Rockwell Medical (RMTI), Axcelis Technologies (ACLS) and Protagonist Therapeutics (PTGX). Company Calendar Last Earnings5/08/2025Today5/24/2025Next Earnings (Estimated)8/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CRVS CIK1626971 Webwww.corvuspharma.com Phone(650) 900-4520FaxN/AEmployees30Year FoundedN/APrice Target and Rating Average Stock Price Target$15.00 High Stock Price Target$21.00 Low Stock Price Target$11.00 Potential Upside/Downside+329.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.98) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-27,030,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-70.71% Return on Assets-45.90% Debt Debt-to-Equity RatioN/A Current Ratio0.92 Quick Ratio0.92 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.79 per share Price / Book4.42Miscellaneous Outstanding Shares68,169,000Free Float44,145,000Market Cap$237.91 million OptionableOptionable Beta0.67 Social Links The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:CRVS) was last updated on 5/24/2025 by MarketBeat.com Staff From Our PartnersTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | Sponsored$19 for a FULL YEAR of stock picks?!Invest in Musk's AI Play With Just $100 You don't need deep pockets to ride the next wave of AI wealth. ...Behind the Markets | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredAfter Monday, price goes up 600% (hurry)Right now, for a limited time… You can get up to 52 Money Monday trades for just $7! Thanks to Wall Street’...Timothy Sykes | SponsoredMemorial Day Sale! 82% Off Disruptors and Dominators!Jensen Huang recently gave the keynote speech at the Consumer Electronics Show in Las Vegas. When the Nvidi...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corvus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Corvus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.